Literature DB >> 34626159

The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach.

Tommy Ivanics1,2,3, Walter Nelson4,5, Madhukar S Patel6, Marco P A W Claasen1,7, Lawrence Lau1, Andre Gorgen1, Phillipe Abreu1, Anna Goldenberg8, Lauren Erdman8,9, Gonzalo Sapisochin1,10.   

Abstract

Liver transplantation (LT) listing criteria for hepatocellular carcinoma (HCC) remain controversial. To optimize the utility of limited donor organs, this study aims to leverage machine learning to develop an accurate posttransplantation HCC recurrence prediction calculator. Patients with HCC listed for LT from 2000 to 2016 were identified, with 739 patients who underwent LT used for modeling. Data included serial imaging, alpha-fetoprotein (AFP), locoregional therapies, treatment response, and posttransplantation outcomes. We compared the CoxNet (regularized Cox regression), survival random forest, survival support vector machine, and DeepSurv machine learning algorithms via the mean cross-validated concordance index. We validated the selected CoxNet model by comparing it with other currently available recurrence risk algorithms on a held-out test set (AFP, Model of Recurrence After Liver Transplant [MORAL], and Hazard Associated with liver Transplantation for Hepatocellular Carcinoma [HALT-HCC score]). The developed CoxNet-based recurrence prediction model showed a satisfying overall concordance score of 0.75 (95% confidence interval [CI], 0.64-0.84). In comparison, the recalibrated risk algorithms' concordance scores were as follows: AFP score 0.64 (outperformed by the CoxNet model, 1-sided 95% CI, >0.01; P = 0.04) and MORAL score 0.64 (outperformed by the CoxNet model 1-sided 95% CI, >0.02; P = 0.03). The recalibrated HALT-HCC score performed well with a concordance of 0.72 (95% CI, 0.63-0.81) and was not significantly outperformed (1-sided 95% CI, ≥0.05; P = 0.29). Developing a comprehensive posttransplantation HCC recurrence risk calculator using machine learning is feasible and can yield higher accuracy than other available risk scores. Further research is needed to confirm the utility of machine learning in this setting.
Copyright © 2021 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34626159     DOI: 10.1002/lt.26332

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection.

Authors:  Matthias Ilmer; Markus Otto Guba
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

2.  Impact of Tumour Biology on Outcomes of Radical Therapy for Hepatocellular Carcinoma Oligo-Recurrence after Liver Transplantation.

Authors:  Kin-Pan Au; James Yan-Yue Fung; Wing-Chiu Dai; Albert Chi-Yan Chan; Chung-Mau Lo; Kenneth Siu-Ho Chok
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

Review 3.  Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?

Authors:  Stéphanie Gonvers; Parissa Tabrizian; Emmanuel Melloul; Olivier Dormond; Myron Schwartz; Nicolas Demartines; Ismail Labgaa
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

Review 4.  Artificial Intelligence: Present and Future Potential for Solid Organ Transplantation.

Authors:  Andrea Peloso; Beat Moeckli; Vaihere Delaune; Graziano Oldani; Axel Andres; Philippe Compagnon
Journal:  Transpl Int       Date:  2022-07-04       Impact factor: 3.842

5.  Deep learning models for predicting the survival of patients with chondrosarcoma based on a surveillance, epidemiology, and end results analysis.

Authors:  Lizhao Yan; Nan Gao; Fangxing Ai; Yingsong Zhao; Yu Kang; Jianghai Chen; Yuxiong Weng
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

Review 6.  Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation.

Authors:  Kohei Ogawa; Yasutsugu Takada
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

Review 7.  Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.

Authors:  Marco Biolato; Tiziano Galasso; Giuseppe Marrone; Luca Miele; Antonio Grieco
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.